ArticleMaterials today. Bio2026
DNA-damage-targeting copper nanoparticles induce cuproptosis for enhanced cancer radiotherapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in ferroptosis and cuproptosis: implications for spinal cord injury.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a cornerstone of cancer therapy but is often undermined by tumor radioresistance arising from insufficient generation of reactive oxygen species (ROS) and limited DNA damage. Cuproptosis-a newly identified form of copper-dependent cell death-offers an innovative, yet untapped, approach to enhance radiosensitivity. Here, we report a first-of-its-kind copper-doped metal-organic framework nanoplatform, based on a ZIF-8 framework and loaded with the copper ionophore elesclomol, to concurrently induce cuproptosis and amplify radiotherapy. This nanoplatform (Cu-MOF@ELS) efficiently shuttles copper into cancer cell mitochondria, triggering excessive reactive oxygen species (ROS) production and mitochondrial dysfunction that synergize with radiation to promote extensive DNA damage. We demonstrate that Cu-MOF@ELS strongly induces cuproptosis in tumor cells and significantly boosts radiotherapeutic efficacy in vitro and in vivo, with treated mice showing pronounced tumor regression and minimal systemic toxicity. Our work pioneers a novel therapeutic paradigm by integrating cuproptosis induction with radiotherapy, establishing Cu-MOF@ELS as a groundbreaking radiosensitizer that exploits metabolic cell-death mechanisms to overcome tumor radioresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.